Novotech, an international contract research organization (CRO), has announced the appointment of Dr. Yooni Kim as Managing Director of the Asia Pacific (APAC) region, effective September 1, 2024.
This strategic move underscores Novotech’s commitment to expanding its global presence and enhancing operational capabilities. The creation of this new position aligns with Novotech’s goals to synchronize its efforts with global and regional developments, including in the U.S., Europe, Mainland China, and APAC.
Dr. Yooni Kim brings over 25 years of expertise in academic research, CRO operations, and pharmaceutical clinical research. She has been with Novotech since 2016, initially as Administrative Director, and played a key role in the company’s expansion in Asia. Following the 2019 merger with PPC Group, Dr. Kim advanced to Vice President of Global Clinical Services, where she led Novotech’s global clinical services division. She holds a pharmacy degree from Ewha Womans University and a doctorate in preventive medicine from Seoul National University.
Dr. John Moller, CEO of Novotech, expressed enthusiasm about Dr. Kim’s appointment, highlighting her deep knowledge of Asia’s clinical research landscape and her leadership skills as critical to strengthening Novotech’s presence in the region.
In her new role, Dr. Kim will oversee Novotech’s APAC operations, guiding various teams and ensuring smooth business operations. She aims to enhance Novotech’s regional capabilities by focusing on customer needs, maintaining strong relationships with key opinion leaders and regulatory bodies, and bolstering partnerships with clinical trial institutions.
Dr. Moller emphasized the importance of this appointment, noting that Dr. Kim’s leadership will be vital for delivering reliable results for Novotech’s clients in APAC. Dr. Kim will also contribute to Novotech’s Standing Committee, aiding in the company’s strategic direction and global initiatives.
Novotech continues to refine its organizational structure to support its mission of being a comprehensive biotechnology partner across all stages of clinical development.
About Novotech
Founded in 1997, Novotech is a leading international CRO specializing in biotechnology partnerships to advance new therapies. The company offers a full range of services, including laboratories, Phase I clinical centers, drug development consulting, and regulatory compliance. Recognized for its industry contributions, Novotech has won multiple awards, including the CRO Leadership Award 2023 and the Asia Pacific Cell and Gene Therapy Clinical Trial Excellence Award 2023. With over 3,000 employees across 34 locations, Novotech is a trusted partner in clinical trials and drug development.
